Total Funding
89
57
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
22350
Geneva-based MedTech spin-off from CERN, specializing in the development and manufacturing of innovative nuclear imaging systems.
Raymond Miralbell: Co-Founder, Chief Scientific Officer- Marcus Palm: Co-founder, CTO
About the Company
Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qualγscan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing
Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.
